TScan Therapeutics Inc
TCRX1.670USD
+0.050+3.09%
交易中 （美東）報價延遲15分鐘
94.51M總市值
虧損本益比TTM
關於 TScan Therapeutics Inc 公司
TScan Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發一系列 T 細胞受體工程 T 細胞 (TCR-T) 療法，用於治療癌症患者。該公司的主要 TCR-T 療法候選藥物 TSC-100 和 TSC-101 正在進行臨牀開發，用於治療血液系統惡性腫瘤患者，以消除殘留疾病並防止異基因造血細胞移植後的復發。該公司還在開發多路複用 TCR-T 療法候選藥物，用於治療各種實體瘤。該公司已經開發並繼續建立其 ImmunoBank，這是 TCR 領域不同人類白細胞抗原 (HLA) 類型的實體瘤靶標集合。該公司正在推進大約六個實體瘤項目：TSC-204、TSC-200、TSC-203、TSC-201、TSC-202 和 TSC-205。
公司簡介
公司代碼TCRX
公司名稱TScan Therapeutics Inc
上市日期Jul 16, 2021
CEOMr. Gavin Macbeath, Ph.D.
員工數量194
證券類型Ordinary Share
年結日Jul 16
公司地址830 Winter Street
城市WALTHAM
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02451
電話18573999500
網址https://www.tscan.com
公司代碼TCRX
上市日期Jul 16, 2021
CEOMr. Gavin Macbeath, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Chrystal U. Louis
Dr. Chrystal U. Louis
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Katina Dorton
Ms. Katina Dorton
Independent Director
Independent Director
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
Dr. Gabriela Gruia, M.D.
Dr. Gabriela Gruia, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
收入明細
FY2025Q1
FY2024
FY2023
FY2022
FY2021
暫無數據
地區USD
名稱
營收
佔比
United States
2.17M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Lynx1 Capital Advisors LLC
15.19%
BVF Partners L.P.
9.35%
K2 HealthVentures LLC
6.89%
Adage Capital Management, L.P.
6.69%
Baker Bros. Advisors LP
5.32%
Other
56.56%
持股股東
持股股東
佔比
Lynx1 Capital Advisors LLC
15.19%
BVF Partners L.P.
9.35%
K2 HealthVentures LLC
6.89%
Adage Capital Management, L.P.
6.69%
Baker Bros. Advisors LP
5.32%
Other
56.56%
股東類型
持股股東
佔比
Investment Advisor
34.77%
Hedge Fund
23.77%
Venture Capital
19.29%
Investment Advisor/Hedge Fund
12.62%
Research Firm
2.10%
Individual Investor
0.39%
Bank and Trust
0.35%
Private Equity
0.09%
Pension Fund
0.02%
Other
6.59%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
191
48.87M
93.41%
-296.84K
2025Q1
198
46.53M
88.95%
-3.07M
2024Q4
184
47.92M
91.75%
+202.11K
2024Q3
172
45.30M
92.65%
-3.14M
2024Q2
147
48.79M
100.07%
+12.56M
2024Q1
110
39.09M
88.67%
+3.45M
2023Q4
95
36.63M
84.04%
+3.23M
2023Q3
84
33.69M
84.61%
-2.13M
2023Q2
78
32.77M
82.58%
-787.78K
2023Q1
72
14.05M
68.89%
-1.92M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Lynx1 Capital Advisors LLC
7.95M
15.19%
+2.59M
+48.32%
May 20, 2025
BVF Partners L.P.
4.89M
9.35%
+1.90M
+63.56%
Mar 31, 2025
K2 HealthVentures LLC
3.60M
6.89%
+2.90M
+414.67%
Dec 31, 2024
Adage Capital Management, L.P.
3.50M
6.69%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
2.78M
5.32%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.61M
4.99%
-57.04K
-2.14%
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
4.5%
-25.79K
-1.08%
Mar 31, 2025
Propel Bio Management, LLC
2.09M
3.99%
--
--
Mar 31, 2025
Pitango Venture Capital
2.08M
3.98%
+2.08M
--
Dec 31, 2023
Checkpoint Capital L.P.
2.02M
3.86%
+261.66K
+14.90%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Simplify Propel Opportunities ETF
2.25%
iShares Health Innovation Active ETF
0.08%
iShares Micro-Cap ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Proshares Ultra Russell 2000
0%
查看更多
Simplify Propel Opportunities ETF
佔比2.25%
iShares Health Innovation Active ETF
佔比0.08%
iShares Micro-Cap ETF
佔比0.01%
ProShares Ultra Nasdaq Biotechnology
佔比0.01%
Invesco Nasdaq Biotechnology ETF
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
